Institute for Evidence in Medicine, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Institute of Medical Biometry and Statistics, Medical Centre - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
BMJ. 2021 Sep 15;374:n1864. doi: 10.1136/bmj.n1864.
To evaluate the agreement between diet-disease effect estimates of bodies of evidence from randomised controlled trials and those from cohort studies in nutrition research, and to investigate potential factors for disagreement.
Meta-epidemiological study.
Cochrane Database of Systematic Reviews, and Medline.
Population, intervention or exposure, comparator, outcome (PI/ECO) elements from a body of evidence from cohort studies (BoE(CS)) were matched with corresponding elements of a body of evidence from randomised controlled trials (BoE(RCT)). Pooled ratio of risk ratios or difference of mean differences across all diet-disease outcome pairs were calculated. Subgroup analyses were conducted to explore factors for disagreement. Heterogeneity was assessed through I and τ. Prediction intervals were calculated to assess the range of possible values for the difference in the results between evidence from randomised controlled trials and evidence from cohort studies in future comparisons.
97 diet-disease outcome pairs (that is, matched BoE(RCT) and BoE(CS)) were identified overall. For binary outcomes, the pooled ratio of risk ratios comparing estimates from BoE(RCT) with BoE(CS) was 1.09 (95% confidence interval 1.04 to 1.14; I=68%; τ=0.021; 95% prediction interval 0.81 to 1.46). The prediction interval indicated that the difference could be much more substantial, in either direction. We further explored heterogeneity and found that PI/ECO dissimilarities, especially for the comparisons of dietary supplements in randomised controlled trials and nutrient status in cohort studies, explained most of the differences. When the type of intake or exposure between both types of evidence was identical, the estimates were similar. For continuous outcomes, small differences were observed between randomised controlled trials and cohort studies.
On average, the difference in pooled results between estimates from BoE(RCT) and BoE(CS) was small. But wide prediction intervals and some substantial statistical heterogeneity in cohort studies indicate that important differences or potential bias in individual comparisons or studies cannot be excluded. Observed differences were mainly driven by dissimilarities in population, intervention or exposure, comparator, and outcome. These findings could help researchers further understand the integration of such evidence into prospective nutrition evidence syntheses and improve evidence based dietary guidelines.
评估随机对照试验和队列研究中证据体的饮食-疾病效应估计值之间的一致性,并探讨不一致的潜在因素。
荟萃流行病学研究。
Cochrane 系统评价数据库和 Medline。
从队列研究(BoE(CS))的证据体中匹配人群、干预或暴露、比较、结局(PI/ECO)元素,与随机对照试验(BoE(RCT))的证据体进行匹配。计算所有饮食-疾病结局对的风险比比或均值差异比的汇总比值。进行亚组分析以探讨不一致的因素。通过 I 和 τ 评估异质性。预测区间用于评估未来比较中随机对照试验和队列研究证据之间结果差异的可能值范围。
总体上确定了 97 个饮食-疾病结局对(即匹配的 BoE(RCT)和 BoE(CS))。对于二分类结局,比较 BoE(RCT)和 BoE(CS)估计值的风险比汇总比值为 1.09(95%置信区间 1.04 至 1.14;I=68%;τ=0.021;95%预测区间 0.81 至 1.46)。预测区间表明,差异可能更大,方向不定。我们进一步探索了异质性,发现 PI/ECO 差异,尤其是在随机对照试验中比较膳食补充剂和队列研究中营养素状态时,解释了大部分差异。当两种证据类型之间的摄入量或暴露类型相同时,估计值相似。对于连续结局,随机对照试验和队列研究之间观察到微小差异。
平均而言,BoE(RCT)和 BoE(CS)估计值之间的汇总结果差异较小。但队列研究中广泛的预测区间和一些显著的统计异质性表明,个别比较或研究中可能存在重要差异或潜在偏倚。观察到的差异主要由人群、干预或暴露、比较和结局的差异驱动。这些发现可以帮助研究人员进一步理解将此类证据整合到前瞻性营养证据综合中,并改进基于证据的饮食指南。